News NICE relents and backs drug for IgAN from CSL Vifor Thousands of people living with rare kidney disease IgAN in the UK will soon be able to access a new oral treatment from CSL Vifor.
News MSD adds new indication for Welireg in rare tumours MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
News Abeona prices rare cell disorder gene therapy at $3.1m Abeona Therapeutics' Zevaskyn has been approved in the US as a treatment for the rare skin disorder recessive dystrophic epidermolysis bullosa (DEB).
News Merck agrees $3.9 billion takeover of SpringWorks Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.
News First drug for rare disease APDS cleared for NHS use Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat APDS, an ultra-rare immunodeficiency disorder.
News Spruce Bio sows the seeds of its new future Spruce has bounced back from the failure of its lead drug last year, thanks to a licensing deal with BioMarin for a late-stage Sanfilippo drug.
News After internal setbacks, Pfizer buys obesity player Metsera Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
